Enasidenib (AG-221) is the first IDH inhibitor approved by the FDA for the treatment of relapsed or refractory acute myeloid leukemia (RR-AML) with IDH2 mutations and achieved good therapeutic effects (50). The gene discussed is IDH2; the disease is acute myeloid leukemia.